Navigation Links
Inflamax Research Chosen to Conduct a Multicenter Environmental Exposure Chamber Phase 3 Study of Ultrashort Grass Allergy Vaccine by Allergy Therapeutics (UK) Ltd.
Date:4/9/2013

Research. In separate discussions, the FDA has advised that EEC data will be accepted as part of pivotal registration trials. Inflamax has several studies in the planning stages which incorporate the mobile EEC technology in hybrid Field/EEC studies which incorporate EEC visits into the traditional allergy field study. Inflamax, on its own will begin the work immediately to set up an Investigator network to conduct the international study across three locations in the US and Canada using Inflamax’s proprietary mobile Environmental Exposure Chamber (mEEC™) system.

Inflamax Research’s mEEC™ system is a patent pending technology developed by Inflamax that allows the incorporation of EEC visits in any field allergic rhinitis study. Mobile EECs are designed such that an EEC site can be positioned at any location worldwide. Once a site is finalized the mobile EEC can be set up in as little as one week. Data collected in the EEC has been shown to be more discriminative, accurate, precise and less variable then data collected in traditional field seasonal or perennial rhinitis studies. Lower data variability also permits studies to have smaller sample sizes leading to cost and time efficiencies in drug development.

About Inflamax

Inflamax is a full service Contract Research Organization (CRO) specializing in Proof of Concept as well as Phase I through IV studies in allergy, asthma, ocular and dermatology utilizing EEC technology. Inflamax conducts single and multi-center Environmental Exposure Chamber (EEC) and field studies. In addition to Inflamax Research’s Mobile EEC(TM) systems which can be positioned globally, Inflamax has 2 fixed EECs at Inflamax headquarters in Toronto, Canada. Inflamax’s EECs have been validated for the study of allergy to ragweed, grass and dry eye syndrome (utilizing low humidity EEC conditions). Validations are currently in process for cat and dust mite allergens and are expected to be completed in Q2’2013, thereby maki
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Inflamax Research Appoints Dr. Anne Marie Salapatek President & Chief Scientific Officer
2. Inflamax Research Introduces Electronic Patient Data Acquisition Tablet™ (ePDAT)™ for Real-Time PRO Data Collection
3. Inflamax Research announces the launch of its Mobile Environmental Exposure Chamber™ for conduct of Allergy & Asthma Trials
4. China Industry Reports: 2013 Research on Swine Industry Chain, Human Tetanus Immunoglobulin, Power Energy Storage Battery and Wind Power Lubricating Grease at ReportsnReports.com
5. Manchester leads the way in graphene membrane research
6. ICMs New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
7. QVC and Fashion Footwear Association of New York Invest in Personalized Breast Cancer Therapy Research
8. Solution Styrene Butadiene Rubber (S-SBR) Market is Expected to Reach USD 3.2 Billion in 2018: Transparency Market Research
9. Elsevier and the Belarus Ministry of Education Honor Researchers with Scopus Awards
10. American Federation for Aging Research Announces Recipients of Irving S. Wright and Vincent Cristofalo Scientific Awards
11. Beekeepers, Researchers and Bayer CropScience Associate Overwintering Bee Losses with Varroa Mite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015  Neogen Corporation (NASDAQ: NEOG ) ... United Kingdom -based Lab M Holdings, ... and diagnostic systems. Lab M was ... provider of microbial testing and diagnostic products for the ... company currently sells into more than 70 countries worldwide, ...
(Date:8/27/2015)... 27, 2015 The National Necrotizing Fasciitis ... life—were saved by doctors at Vanderbilt University Hospital in ... NovaBay Pharmaceuticals and Dr. John Crew , director ... Seton Medical Center in Daly City, CA. ... breakthrough approach, pioneered by Dr. Crew, that had previously ...
(Date:8/27/2015)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... 2015. Biorem,s complete second quarter financial statements and MD&A have been ... except earnings per shareThree-months ended , Six -months endedJune 30 , ... , 2014 Revenue , 4,709 , ... , 1,656 , 56 , 3,188 ...
(Date:8/27/2015)... 27, 2015 GlassesOff (OTCBB: GLSO), a ... in the human vision system, announced today a partnership with ... Chris Paul to develop a new mobile app ... improve their real-life on-court performance. Vision is the ... is shooting a ball or blocking a pass. The critical ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3
... 10, 2011 Enobia Pharma Inc., today announced that ... ENB-0040, a bone targeted enzyme replacement therapy being investigated ... bone disorder. The results were presented by Robert Heft, ... the 29th Annual J.P. Morgan Healthcare Conference in San ...
... 10, 2011 Entrega, Inc., a new company ... formation by Enlight Biosciences, a Boston-based company established ... pharmaceutical companies. As part of its initial development ... drug delivery platform to create orally bioavailable formulations ...
... Aratana Therapeutics, a newly-formed company focused on the development of ... it has closed a $20 million Series A financing led ... we will be focused on taking advancements from the human ... and care for animals," said Dr. David Rosen, President and ...
Cached Biology Technology:Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 2Enobia Announces Successful Completion of Phase II Juvenile Study of ENB-0040, a Bone Targeted Enzyme Replacement Therapy 3New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 2New Oral Biologics Delivery Company, Entrega, Announces Strategic Partnership with Pharma 3
(Date:8/5/2015)... CHICAGO , August 5, 2015 ... Identity & Access Management Market by Software, Services, Vertical (BFSI, ... Chemical/Pharma), & Geography - Global Forecast to 2020", published ... Access Management Market globally into various segments. The global ... in 2014 to $546.2 Million by 2019, at a ...
(Date:8/3/2015)... Synaptics, Inc. (Nasdaq: SYNA ), the ... members of the executive management team will present to ... Leadership Forum on Tuesday, August 11, 2015 at 1:00 ... the Sonnenalp Resort in Vail, CO. ... information. An audio webcast of the event will be ...
(Date:7/31/2015)... La 10 th International Conference on Genomics ... 22 al 25 de octubre de 2015 en ... conferencia celebra su décimo aniversario. Desde su inauguración en el ... reuniones anuales más influyentes del mundo en el campo ,ómico, ... y mejores a nivel científico. ICG-10 se ...
Breaking Biology News(10 mins):Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... CAMBRIDGE, Mass., Oct. 20, 2010 -- Microbes living at the ... of the gaseous waste from the Deepwater Horizon oil spill ... miles of the spill site. A paper on that ... ago today, will appear in a forthcoming issue of the ...
... reducing the cost of certain catalysts substances that ... of super-strong forms of the world,s most widely used ... issue of Chemical & Engineering News (C&EN), ... led to availability of stronger, more durable consumer products ...
... BOSTON (October 20, 2010) - People who consume several ... of refined grains appear to have less of a type ... triggering cardiovascular disease and type 2 diabetes, a new study ... Center on Aging (USDA HNRCA) at Tufts University observed lower ...
Cached Biology News:Microbes may consume far more oil-spill waste than earlier thought 2Eating mostly whole grains, few refined grains linked to lower body fat 2
... expertise that made the original Gene Pulser apparatus ... available has been applied in the Gene Pulser ... modular design of the Gene Pulser II system ... that has the widest range of settings to ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... discovery system miniaturizes, integrates and automates ... LabChip technology, the LabChip 3000 performs ... flow fashion. LabChip assays are separations-based, ... what is achievable in homogenous, well-based ...
...
Biology Products: